study_start,study_end,eligible_patients,treated_patients,treated_paxlovid,treated_sotrovimab,treated_remdesivir,treated_molnupiravir,treated_casirivimab,high_risk_cohort_2plus,high_risk_cohort_lower,high_risk_cohort_upper
2021-12-11,2022-07-01,115200,22120,6020,10980,40,5040,50,18750,1,6
